English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Delayed wound healings in diabetic patients are related with t he impairment of the expressions of various growth factors. Treatments using growth factors have been attempted on diabetic foot ulcer. VEGF (vascular endothelial growth factor) accelerates neo-angiogenes is on the early phase of the wound healing and exerts chemo-attractive effe ct for the other growth factors and cytokines. Non-viral gene transfer strategies are attractive tool for the gene therapy due to the safety and the versatility, but the low efficiency has been the serious problem. Methods: We performed the VEGF gene therapy using reconstructed minicircle MINI-pβ VEGF DNA with a polymeric carrier, polyethylenimine (PEI, 25 kDa) in HEK293, CHO, and NIH3T3 cell lines, and compared its efficiency with the conventional VEGF plasmid pβVEGF. Results: The levels of expressed VEGF were higher in the groups using BP EI (branched PEI) as a gene carrier than naked plasmid transfer in all cell lines (P < 0.05). The minicircle MINI-pβVEGF DNA showed much higher VEGF expression than conventional plasmid pβVEGF (P < 0.05). Conclusion: Minicircle DNA MINI-pβVEGF showed much higher transfection efficiency than conventional plasmid pβ VEGF. It might be used in actual human clinical trial due to it s higher efficiency and possible safety for the treatment of diabetic foot ulcer. (J Kor Diabetes Assoc 31:465~471, 2007)

Comparison of Minicircle with Conventional Plasmid for the Non-viral Vascular Endothelial Growth Factor (VEGF) Gene Therapy